NasdaqGS - Nasdaq Real Time Price USD
Solid Biosciences Inc. (SLDB)
At close: November 5 at 4:00 PM EST
Pre-Market: 9:14 AM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
8,094.00
13,620.00
--
Operating Expense
100,029.00
104,315.00
107,368.00
85,874.00
86,462.00
Operating Income
-100,029.00
-104,315.00
-99,274.00
-72,254.00
-86,462.00
Net Non Operating Interest Income Expense
8,548.00
7,142.00
2,616.00
64.00
115.00
Other Income Expense
790.00
1,158.00
10,677.00
2.00
-1,943.00
Pretax Income
-90,691.00
-96,015.00
-85,981.00
-72,188.00
-88,290.00
Net Income Common Stockholders
-90,691.00
-96,015.00
-85,981.00
-72,188.00
-88,290.00
Diluted NI Available to Com Stockholders
-90,691.00
-96,015.00
-85,981.00
-72,188.00
-88,290.00
Basic EPS
-3.29
-4.83
-10.10
-10.14
-25.50
Diluted EPS
-3.29
-4.83
-10.10
-10.14
-25.50
Basic Average Shares
29,847.18
19,884.01
8,512.09
7,118.02
3,462.48
Diluted Average Shares
29,847.18
19,884.01
8,512.09
7,118.02
3,462.48
Total Operating Income as Reported
-100,029.00
-104,252.00
-106,452.00
-72,254.00
-88,406.00
Total Expenses
100,029.00
104,315.00
107,368.00
85,874.00
86,462.00
Net Income from Continuing & Discontinued Operation
-90,691.00
-96,015.00
-85,981.00
-72,188.00
-88,290.00
Normalized Income
-90,691.00
-96,078.00
-97,039.00
-72,188.00
-86,346.00
Interest Income
8,498.00
7,142.00
2,616.00
64.00
115.00
Net Interest Income
8,548.00
7,142.00
2,616.00
64.00
115.00
EBIT
-99,041.00
-104,315.00
-99,274.00
-72,254.00
-86,462.00
EBITDA
-96,678.00
-101,734.00
-96,866.00
-69,290.00
-82,540.00
Reconciled Depreciation
2,363.00
2,581.00
2,408.00
2,964.00
3,922.00
Net Income from Continuing Operation Net Minority Interest
-90,691.00
-96,015.00
-85,981.00
-72,188.00
-88,290.00
Total Unusual Items Excluding Goodwill
--
63.00
11,058.00
--
-1,944.00
Total Unusual Items
--
63.00
11,058.00
--
-1,944.00
Normalized EBITDA
-96,678.00
-101,797.00
-107,924.00
-69,290.00
-80,596.00
12/31/2020 - 1/26/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
LXEO Lexeo Therapeutics, Inc.
8.03
-2.55%
ALGS Aligos Therapeutics, Inc.
9.83
+3.69%
VYGR Voyager Therapeutics, Inc.
6.65
0.00%
ADVM Adverum Biotechnologies, Inc.
7.72
+2.39%
SVRA Savara Inc.
3.6200
-2.16%
RGNX REGENXBIO Inc.
8.92
+1.83%
ANNX Annexon, Inc.
7.25
+2.26%
ANAB AnaptysBio, Inc.
19.88
-0.30%
MDNAF Medicenna Therapeutics Corp.
1.7400
+1.16%
CABA Cabaletta Bio, Inc.
4.2000
+5.00%